HDACs/mTOR Inhibitor 1 |
| Catalog No.GC65460 |
HDAC/mTOR 억제제 1은 혈액 악성종양을 치료하기 위한 이중 히스톤 탈아세틸화효소(HDAC) 및 포유동물 표적 라파마이신(mTOR) 표적 억제제이며, HDAC1, HDAC6의 경우 IC50이 0.19nM, 1.8nM, 1.2nM 및 >500nM입니다. 각각 PI3Kα. HDAC/mTOR 억제제 1은 G0/G1 단계에서 세포 주기 정지를 자극하고 생체 내에서 낮은 독성으로 종양 세포 사멸을 유도합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2271413-06-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
HDACs/mTOR Inhibitor 1 is a dual Histone Deacetylases (HDACs) and mammalian target of Rapamycin (mTOR) target inhibitor for treating hematologic malignancies, with IC50s of 0.19 nM, 1.8 nM, 1.2 nM and >500 nM for HDAC1, HDAC6, mTOR and PI3Kα, respectively. HDACs/mTOR Inhibitor 1 stimulates cell cycle arrest in G0/G1 phase and induce tumor cell apoptosis with low toxicity in vivo[1].
[1]. Chen Y, et al. Discovery of a Novel Dual Histone Deacetylases (HDACs) and Mammalian Target of Rapamycin (mTOR) Target Inhibitor as a Promising Strategy for Cancer Therapy. J Med Chem. 2019 Jan 10.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *